Development activities are intended to support regulatory filings for S0812 and additional promising bitter blockers
SAN DIEGO, CA, February 9, 2009 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX), a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that it has initiated development activities for S0812 and additional new bitter blockers. The development phase includes scale-up production activities and safety studies to support regulatory filings for the bitter blockers in the U.S. and elsewhere.
"Senomyx has two collaborators for our Bitter Blocker Program. We are pleased to report that S0812 and additional bitter blockers met the criteria established by one of our collaborators for reducing the bitterness of their products," stated Kent Snyder, President, Chief Executive Officer, and Chairman of the Board of the Company. "In conjunction with that collaborator, Senomyx has decided to initiate development activities intended to support regulatory filings for these promising bitter blockers."
"In addition to our two existing collaborations for the Bitter Blocker Program, we are using our proprietary technologies to create a novel 'toolbox' of bitter blockers that have the potential to be licensed to new partners to reduce the bitter taste of a wide variety of food, beverage, OTC healthcare, and pharmaceutical products," said Mark Zoller, Ph.D., Senomyx's Chief Scientific Officer and Executive Vice President of Discovery and Development.
"We believe that Senomyx's Bitter Blocker Program has the potential to generate meaningful long-term value for the Company," noted John Poyhonen, Senior Vice President, Chief Financial and Business Officer. "Reducing bittern
|SOURCE Senomyx, Inc.|
Copyright©2009 PR Newswire.
All rights reserved